### Type of Article:

### Original, Review, Meta-analysis, Case Report, Case series, or other type of Article

**Title**

**Author full name1, Author full name2,Author full name3**

1.Author’s 1 affiliations

2. Author’s 2 affiliations

3. Author’s 3 affiliations

**\*Corresponding author:**

**Full name**

affiliations

Email: xxxxxxxx@xxxxxx.xxx

Contact phone number (optional)

**ABSTRACT (**Maximum 250 words**)**

**Background:**

**Objective:**

**Methods:**

**Results:**

**Conclusions:**

**Keywords:** 3 – 5 keywords

1. **INTRODUCTION**
2. **METHODS**
3. **RESULTS**

Put the whole results text to interpret your findings here for each table and or figure , at the end of each paragraph mention the number of table or figure that referred to , example (Table 1), (Table 2). (Figure 1), (Figure 2).

Then insert your tables and figures below the results text

Table 1 Example table (Title of the table) for single group

|  |  |  |
| --- | --- | --- |
| Variable | No. | % |
|  |  |  |
|  |  |  |

Table 2. Example table (Title of the table) for two groups

|  |  |  |
| --- | --- | --- |
| Variable | Group 1 | Group 2 |
| No. | % | No. | % |
| Variable 1 |  |  |  |  |
| Variable 2 |  |  |  |  |
| Variable 3 |  |  |  |  |
| Variable 4 |  |  |  |  |

Figure 1: Bar-Chart showing the …… (Title of Figure)

Figure 2: Pie-Chart showing the distribution of categories among the studied group

1. **DISCUSSION**

Discuss your findings and compare to previous studies or literatures relevant to your study, do not repeat the results in this section , but explain and compare

1. **CONCLUSION**

Summarize your findings here, you can also suggest some recommendations

**ACKNOWLEDGEMENTS**

If any.

**DECLARATIONS**

**Ethical approval**: Should be clearly declared in accordance with [the 2013 declaration of Helsinki of the World Medical association (WMA)](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)

**Funding**: If any, mention the funding agencies or individuals who funded the study, otherwise state “None, Self-funded by the authors”

**Conflict of interest**: If any, otherwise, state “none declared by authors”

1. **REFERENCES (Vancouver style)**
2. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63.
3. O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005:607-29.
4. National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014.

|  |
| --- |
| **General guidelines on references**References should be numbered consecutively as they appear in the text. Reference citations in the text should be identified by numbers in superscript after the punctuation marks. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six should be quoted followed by et al. |
| *Journal article:*Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63.*Book chapter:*O'Brien C. Drug addiction and drug abuse. In: Brunton LB, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005: 607-629.*Website:*National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 June 2014. |